Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00867217 · ClinicalTrials.gov registry record · Phase 2
Vitamin D3 for Aromatase Inhibitor Induced Arthralgias
A Phase 2 study, sponsored by Qamar Khan.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT00867217: Completed Phase 2 study, sponsored by Qamar Khan.
NCT00867217 is a Phase 2 study that has completed, run by Qamar Khan. The registered enrollment target is 160 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00867217, a Phase 2 study, has completed, sponsored by Qamar Khan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
The primary purpose is to determine if high dose vitamin D3 reduces the incidence of musculoskeletal symptoms associated with the aromatase inhibitor letrozole in women with early stage breast cancer and low serum vitamin D levels.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DRUG Letrozole 2.5mg
- DIETARY_SUPPLEMENT High Dose Vitamin D
- DIETARY_SUPPLEMENT Standard Dose Vitamin D3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00867217
The ClinicalTrials.gov registry entry for NCT00867217 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Qamar Khan, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00867217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00867217 about?
NCT00867217 is a clinical study titled "Vitamin D3 for Aromatase Inhibitor Induced Arthralgias". The primary purpose is to determine if high dose vitamin D3 reduces the incidence of musculoskeletal symptoms associated with the aromatase inhibitor letrozole in women with early stage breast cancer and low serum vitamin D levels.
What is the current status of trial NCT00867217?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2009-03. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00867217?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Letrozole 2.5mg (DRUG), High Dose Vitamin D (DIETARY_SUPPLEMENT), Standard Dose Vitamin D3 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00867217?
This trial is sponsored by Qamar Khan, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.